ANI Pharmaceuticals (ANIP) vs Ocular Therapeutix (OCUL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ANI Pharmaceuticals (ANIP) has outperformed Ocular Therapeutix (OCUL) over the past year, losing 21.5% versus a loss of 37.2%. Over five years, ANIP leads with a +86.6% price change compared with -35.4% for OCUL. ANI Pharmaceuticals is the larger company by market cap ($1.66 billion vs $1.62 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIP | OCUL |
|---|---|---|
| Share price | $72.43 | $7.38 |
| Market cap | $1.66B | $1.62B |
| 1-day change | +0.70% | +2.06% |
| YTD return | -8.88% | -40.44% |
| 1-year return | -21.54% | -37.24% |
| 5-year return | +86.64% | -35.39% |
| P/E ratio (TTM) | 15.68 | — |
| Forward P/E | 7.12 | — |
| EPS (TTM) | $4.62 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $97.00 | $16.44 |
| 52-week low | $69.58 | $6.23 |
| Distance from 52-week high | -25.33% | -55.12% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +46.04% | +267.14% |
| Average volume | 372.56K | 2.78M |
| Shares outstanding | 22.96M | 219.62M |
| Employees | 970 | 325 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIP has outperformed OCUL by 15.7 percentage points over the past year.
About ANI Pharmaceuticals
ANIP stock →ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
ANIP vs OCUL FAQ
Which is bigger, ANI Pharmaceuticals or Ocular Therapeutix?
ANI Pharmaceuticals (ANIP) is larger, with a market capitalization of $1.66B compared with $1.62B for Ocular Therapeutix (OCUL).
Which stock has performed better over the past year, ANIP or OCUL?
ANIP returned -21.54% over the past 12 months, compared with -37.24% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are ANI Pharmaceuticals and Ocular Therapeutix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.